RGS17, regulator of G protein signaling 17, 26575

N. diseases: 35; N. variants: 12
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024809
Disease: Marijuana Abuse
Marijuana Abuse 		0.310 Biomarker disease PSYGENET The G allele of SNP rs596359, in the RGS17 promoter region, was associated with AD, CD, OD, or MjD in both populations (0.005≤P(empirical)≤0.019). 22591552 2012
CUI: C0024809
Disease: Marijuana Abuse
Marijuana Abuse 		0.310 GeneticVariation disease BEFREE The G allele of SNP rs596359, in the RGS17 promoter region, was associated with AD, CD, OD, or MjD in both populations (0.005≤P(empirical)≤0.019). 22591552 2012
CUI: C0236804
Disease: Amphetamine Addiction
Amphetamine Addiction 		0.300 Biomarker disease CTD_human Genome-wide association for methamphetamine dependence: convergent results from 2 samples. 18316681 2008
CUI: C0236807
Disease: Amphetamine Abuse
Amphetamine Abuse 		0.300 Biomarker disease CTD_human Genome-wide association for methamphetamine dependence: convergent results from 2 samples. 18316681 2008
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.140 GeneticVariation disease GWASDB Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. 23535732 2013
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.140 Biomarker disease BEFREE Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures. 29351497 2018
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.140 Biomarker disease BEFREE Our findings revealed that miR-203/RGS17 axis might be a potential therapeutic target for the treatment of PCa. 31298318 2019
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.140 Biomarker disease BEFREE Two compounds, sanguinarine (1) and celastrol (2), were found to be cytostatic against lung and prostate cancer cell lines and cytotoxic against prostate cancer cell lines in vitro, although the dependence of RGS17 on these phenomena remains elusive, a result that is perhaps not surprising given the multimodal cytostatic and cytotoxic activities of many natural products. 28621943 2017
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.140 Biomarker disease BEFREE RGS17: an emerging therapeutic target for lung and prostate cancers. 23734683 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.130 GeneticVariation disease GWASCAT Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. 23535732 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.130 Biomarker disease BEFREE Screen Targeting Lung and Prostate Cancer Oncogene Identifies Novel Inhibitors of RGS17 and Problematic Chemical Substructures. 29351497 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.130 Biomarker disease BEFREE Our findings revealed that miR-203/RGS17 axis might be a potential therapeutic target for the treatment of PCa. 31298318 2019
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.130 Biomarker disease BEFREE Two compounds, sanguinarine (1) and celastrol (2), were found to be cytostatic against lung and prostate cancer cell lines and cytotoxic against prostate cancer cell lines in vitro, although the dependence of RGS17 on these phenomena remains elusive, a result that is perhaps not surprising given the multimodal cytostatic and cytotoxic activities of many natural products. 28621943 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.130 GeneticVariation disease GWASCAT Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 29892016 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.050 GeneticVariation disease BEFREE A region-wide scan across 6q23-25 found significant association between lung cancer susceptibility and three single nucleotide polymorphisms in the first intron of the RGS17 gene. 19351763 2009
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.050 AlteredExpression disease BEFREE Taken together, these data have provided the first evidence of miRNA regulation of RGS17 expression in lung cancer. 20420807 2010
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.050 Biomarker disease BEFREE Besides, miRNA-199 may inhibit the malignant progression of LCa by interacting with RGS17. 31081094 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.050 AlteredExpression disease BEFREE Increased RGS17 expression in some prostate and lung cancers has been demonstrated to support cancer progression, while reduced expression of RGS17 can lead to development of chemotherapeutic resistance in ovarian cancer. 23734683 2013
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.050 Biomarker disease BEFREE Single nucleotide polymorphisms (SNP) on chromosomal regions 5p15.33, 6p21.33, 6q23-25/RGS17, and 15q24-25.1 were assessed for their associations with familial lung cancer. 20142248 2010
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.040 AlteredExpression disease BEFREE Taken together, these data have provided the first evidence of miRNA regulation of RGS17 expression in lung cancer. 20420807 2010
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.040 GeneticVariation disease BEFREE A region-wide scan across 6q23-25 found significant association between lung cancer susceptibility and three single nucleotide polymorphisms in the first intron of the RGS17 gene. 19351763 2009
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.040 Biomarker disease BEFREE Single nucleotide polymorphisms (SNP) on chromosomal regions 5p15.33, 6p21.33, 6q23-25/RGS17, and 15q24-25.1 were assessed for their associations with familial lung cancer. 20142248 2010
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.040 Biomarker disease BEFREE Besides, miRNA-199 may inhibit the malignant progression of LCa by interacting with RGS17. 31081094 2019
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.040 AlteredExpression disease BEFREE Taken together, these data have provided the first evidence of miRNA regulation of RGS17 expression in lung cancer. 20420807 2010
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.040 Biomarker disease BEFREE Besides, miRNA-199 may inhibit the malignant progression of LCa by interacting with RGS17. 31081094 2019